<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1717549828521399&amp;ev=PageView&amp;noscript=1">
Blog Feature

By: Kevin Asp on February 17th, 2016

Print/Save as PDF

Join Us At The AAST Spring Course For Michael Zachek's Talk on Life Safety

Sleep Technologist Advice

SafetyMain.jpg

Meet our speaker Michael Zachek, MD

Zachek_headshot_1.jpg

Get to know  Michael, Director of Sleep Medicine at The Physicians Center for Sleep Disorders

Dr. Zachek is a graduate of the Georgetown University School of Medicine, and completed his internship and residency in Internal Medicine at Duke University prior to entering the United States Air Force.He served as a fellow in Pulmonary Medicine at USAFB Scott and at Barnes Hospital, Washington University and subsequently assumed the position of Chief of Pulmonary Medicine at Wright-Patterson Medical Center, where he was an Assistant Professor of Medicine at Wright State University. He currently practices in Bowling Green, Kentucky and is an Assistant Clinical Professor of Medicine at the University of Louisville and the University of Kentucky.   He serves on the board of the American Lung Association of Kentucky and is President of the Board of the Kentucky Sleep Society. He is board certified in Internal Medicine, Pulmonary Medicine, Critical Care Medicine, and Sleep Disorders.

Dr. Zachek is the director of sleep medicine at the Physicians Center for Sleep Disorders, and directs the sleep centers at Ohio County Hospital and Twin Lakes Regional Hospital. He is on the National Speakers Bureau for BI (Mirapex and Spiriva), GSK (Requip and Advair), Cephalon (Provigil), Jazz (Xyrem), Takeda (Rozerem), Astra Zeneca (Symbicort and Pulmicort), Sanofi Aventis (Lovenox) and Sepracor (Brovana, Xopenex, and Lunesta).

His recent research interests in sleep medicine include device and medical treatment of patients with obstructive sleep apnea (OSA) who continue to experience significant daytime sleepiness (EDS), and evaluation of narcoleptic patients using sodium oxybate and modafinil in combination. He is participating in a nationwide evaluation of CEP-10953 (R-Modafinil) in OSA patients with continued EDS who have depression.

Here's what to expect: 

Saturday, March 12, 10:15 - 11:45 a.m.

"Life Safety"

Course Objectives

  • Identify patients with comorbidities
  • Prepare a safe environment for patients of all ages
  • Define facility access issues
  • Describe medication storage and access requirements 

To Register for the AAST Spring Course in Louisville, click the link below

New Call-to-action
 

About Kevin Asp

Because of the implementation of his best practices of Implementing Inbound Marketing in its Medical Practice, he turned the once stagnant online presence of Alaska Sleep Clinic to that of "The Most Trafficked Sleep Center Website in the World" in just 18 months time.

  • Connect with Kevin Asp